Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2021-12-08 Declaration of Voting R…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of a specific date (November 30, 2021). This type of mandatory monthly disclosure regarding the total share capital and voting rights structure is a specific regulatory filing in France. Among the provided codes, this content most closely aligns with notifications concerning changes in share capital or major shareholdings, but the specific nature of reporting total voting rights monthly points towards a mandatory disclosure that often falls under general regulatory reporting or share capital updates. Since it details the total number of shares and voting rights, it is a notification about the capital structure. The closest fit among the options is 'Major Shareholding Notification' (MRQ) as these reports often accompany or are related to changes in capital structure visibility, or 'Share Issue/Capital Change' (SHA). However, the most precise category for mandatory monthly disclosure of total voting rights/shares, which is a recurring regulatory requirement, is often captured under general regulatory filings if a more specific code isn't available. Given the options, 'Major Shareholding Notification' (MRQ) is often used for disclosures related to the denominator of ownership calculations, or 'Share Issue/Capital Change' (SHA). Since this is a routine monthly update on the total count, and not necessarily a transaction (like POS) or a specific threshold breach notification (MRQ), it is a fundamental capital structure disclosure. In many contexts, routine capital structure updates are classified under 'Share Issue/Capital Change' (SHA) or as a general regulatory filing (RNS). Given the explicit focus on the total number of shares and voting rights, which is a key component of capital structure reporting, SHA is a strong candidate, but RNS is the fallback for mandatory regulatory disclosures not perfectly matching others. Let's re-evaluate the definitions. This is not an ER, IR, 10-K, or CT. It is a mandatory regulatory disclosure about the capital base. Since there isn't a specific 'Total Voting Rights Disclosure' code, and it's a routine regulatory update, RNS (Regulatory Filings) is the safest fallback, although SHA relates to the underlying subject matter (capital). Given the French context where these monthly reports are standard, and they are not explicitly about a transaction (SHA/POS) or a major shareholder crossing a threshold (MRQ), RNS is the most appropriate general regulatory category for this mandatory monthly update.
2021-12-08 French
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and announces that the CEO will participate in a virtual fireside chat at the "4TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE" on a specific future date (December 2, 2021). This is an announcement about a future investor event, not the release of a formal financial report (like 10-K, IR, or ER) or a transcript of a past event. Since the document is an announcement regarding participation in an investor conference, it falls under the general category of investor relations communication. While there isn't a specific code for 'Conference Presentation Announcement,' the closest fit among the provided options that covers general investor updates and presentations is 'Investor Presentation' (IP) or, if it's just an announcement of attendance, it might default to a general regulatory/investor filing category. Given the context of presenting at an investor conference, 'Investor Presentation' (IP) is the most appropriate classification, as these announcements often precede or accompany investor materials. However, since this is purely an announcement of *attendance* at a conference, and not the presentation material itself, it is more accurately classified as a general regulatory/investor announcement, which often falls under RNS if no better fit exists. Reviewing the definitions, 'IP' is for the presentation itself. This is an announcement *about* participation. Since it is a specific, non-standard announcement, and not a core financial report, RNS (Regulatory Filings - general fallback) is a strong candidate, but given the focus on investor events, I will re-evaluate. If the company were announcing the *release* of a presentation, RPA would fit. Since it's announcing participation in a third-party conference, and it's not a core financial filing, RNS is the safest fallback. However, many such announcements are treated as Investor Relations updates. Given the options, and the nature of the announcement (CEO participation in an investor conference), it is a communication aimed at investors. If we strictly follow the definitions, it doesn't fit perfectly. It is not a Call Transcript (CT), Earnings Release (ER), or Investor Presentation (IP) (which implies the presentation document). Therefore, the general regulatory/investor announcement fallback, RNS, is the most suitable classification.
2021-11-17 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that the CEO of Nanobiotix will participate in the '4th Evercore ISI HealthCONx Conference' on a specific date. This is an announcement about a future event (a conference presentation) where company management will speak, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed investor presentation (IP). Since it is an announcement regarding management participation in an external event, it most closely aligns with general corporate communications. Given the options, this type of announcement—a brief update about executive participation in an industry event—does not fit perfectly into the specific categories like ER, CT, or IP. It is a general corporate update. However, since it is a press release announcing management's activity, and it is not a formal regulatory filing that fits elsewhere, it is best classified as a general Regulatory Filing (RNS) or potentially related to Investor Presentation (IP) if it contained slides, but since it's just an announcement of attendance, RNS serves as the best general corporate announcement fallback.
2021-11-17 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 90% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces new preclinical data to be presented at the 36th annual meeting of the Society for the Immunotherapy of Cancer (SITC). It details scientific findings, clinical trial progress (Study 1100), and future development plans for the drug NBTXR3. This format—a formal announcement of scientific/clinical updates, often timed around a conference presentation—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release detailing financial/operational updates (clinical data, trial progress, future outlook) rather than a full, comprehensive report (like 10-K or IR), and it is not explicitly a transcript (CT) or a proxy statement (DEF 14A), the most appropriate classification is Earnings Release (ER), as these often contain the key highlights of recent operational progress. However, given the content is purely scientific/clinical data presentation announcement, and not focused on quarterly financial performance highlights (which is the primary driver for ER), it fits better as a general announcement of material information. Since it is a press release announcing data presentation and clinical progress, and it doesn't fit the specific definitions of MANG, DIRS, DIV, etc., it defaults to a general regulatory announcement or a specific type of operational update. Because it is a press release announcing key operational/scientific progress, ER is plausible, but RNS (Regulatory Filings - fallback) is also strong. Given the context of biotech updates, ER often covers major data readouts. I will lean towards ER as it communicates key performance/progress highlights, which is the essence of an ER, even if the content is scientific rather than purely financial metrics. FY 2021
2021-11-09 French
Inside Information / Other news releases
Regulatory Filings Classification · 90% confidence The document is explicitly titled "*PRESS RELEASE*" and announces that new preclinical data for NBTXR3 will be presented at the 36th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC). It details the findings and mentions ongoing clinical studies (Study 1100). This is a standard format for a company announcing scientific or clinical updates, often preceding a formal presentation or publication. Since it is a press release announcing scientific data presentation and updates on clinical trials, it is not a full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing like a DVA or DIV. It is an announcement of scientific progress, which fits best under the general category of Investor Relations material, but given the specific options, it is most closely aligned with an Earnings Release (ER) if it were summarizing financial results, or a Regulatory Filing (RNS) if it were a general announcement. However, because it is a press release detailing scientific/clinical progress and data presentation, and not a formal financial report, it functions as a general corporate update. Since it is not a formal financial report, but a release of information, and it doesn't fit the specific categories like DIRS, DIV, or MANG, the most appropriate general category for a press release announcing scientific/clinical progress is often RNS (Regulatory Filings/General Announcements), or potentially ER if it were tied to a reporting period, but here it is tied to a conference presentation. Given the context of biotech updates, this is a common form of corporate communication. I will classify it as RNS as it is a general regulatory/corporate announcement that doesn't fit the more specific financial or governance codes.
2021-11-09 English
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled "STATEMENT OF TOTAL VOTING RIGHTS AND SHARES FORMING THE COMPANY'S SHARE CAPITAL" and references specific regulatory articles from the French Commercial Code and the AMF (Autorité des Marchés Financiers). It provides a table detailing the number of outstanding shares and the total gross and net voting rights as of a specific date (October 31, 2021). This type of mandatory disclosure regarding the total number of voting rights is a specific regulatory filing, often related to shareholder structure or meeting prerequisites. Among the provided codes, 'DVA' (Declaration of Voting Results & Voting Rights Announcements) is the most appropriate fit, as it directly concerns the announcement of voting rights figures, even if it's not the final result of a vote, but the underlying capital structure relevant to voting. It is a specific regulatory announcement, not a general report (10-K, IR) or a general regulatory filing (RNS).
2021-11-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.